Gilead-partnered Vienna-based immunotherapy company Hookipa makes Nasdaq debut with downsized $84M IPO

Gilead-partnered Vienna-based immunotherapy company Hookipa makes Nasdaq debut with downsized $84M IPO

Source: 
Endpoints
snippet: 

Gilead-partnered immunotherapy developer Hookipa has been working on technology using arenaviruses — a family of viruses typically hosted by rodents — to turbocharge the human immune system to fight infectious diseases and cancers. The Vienna-based company on Wednesday priced a downsized IPO at the low end of its range at $14, raising gross proceeds of $84 million.